nach oben

European Journal of Clinical Microbiology & Infectious Diseases

Erschienen in:

28.11.2019 | Original Article

Identification of Mycobacterium abscessus species and subspecies using the Cas12a/sgRNA-based nucleic acid detection platform

verfasst von: Guohui Xiao, Su Zhang, Zhihang Liang, Guanqiang Li, Mutong Fang, Yaya Liu, Juanjuan Zhang, Min Ou, Xing He, Tianyu Zhang, Changchun Zeng, Lei Liu, Guoliang Zhang

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

The rapidly growing mycobacterium Mycobacterium abscessus is a clinically important organism causing pulmonary and skin diseases. The M. abscessus complex is comprised of three subspecies: M. abscessus subsp. abscessus, M. abscessus subsp. massiliense, and M. abscessus subsp. bolletii. Here, we aimed to develop a Cas12a/sgRNA-based nucleic acid detection platform to identify M. abscessus species and subspecies. By designing specific sgRNA probes targeting rpoB and erm(41), we demonstrated that M. abscessus could be differentiated from other major mycobacterial species and identified at the subspecies level. Using this platform, a total of 38 clinical M. abscessus isolates were identified, 18 as M. abscessus subsp. abscessus and 20 as M. abscessus subsp. massiliense. We concluded that the Cas12a/sgRNA-based nucleic acid detection platform provides an easy-to-use, quick, and cost-effective approach for identification of M. abscessus species and subspecies.

Nur mit Berechtigung zugänglich

Donohue MJ, Wymer L (2016) Increasing prevalence rate of nontuberculous mycobacteria infections in five states, 2008–2013. Annals of the American Thoracic Society 13:AnnalsATS.201605-353OC

Donohue MJ (2018) Increasing nontuberculous mycobacteria reporting rates and species diversity identified in clinical laboratory reports. BMC Infect Dis 18:163CrossRef

Yu X, Liu P, Liu G, Zhao L, Hu Y, Wei G, Luo J, Huang H (2016) The prevalence of non-tuberculous mycobacterial infections in mainland China: systematic review and meta-analysis. J Infect 73:558CrossRef

Harris KA, Kenna DTD, Cornelis B, Hartley JC, Turton JF, Paul A, Dixon GLJ (2012) Molecular fingerprinting of Mycobacterium abscessus strains in a cohort of pediatric cystic fibrosis patients. J Clin Microbiol 50:1758–1761CrossRef

Won-Jung K, Kyeongman J, Nam Yong L, Bum-Joon K, Yoon-Hoh K, Seung-Heon L, Young Kil P, Ki KC, Sung Jae S, Huitt GA (2011) Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med 183:405CrossRef

Rebecca G, Byrd TF (2008) Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria. Antimicrob Agents Chemother 52:2019–2026CrossRef

Toidi A, Pierre B, Didier R, Michel D (2006) rpoB gene sequence-based characterization of emerging non-tuberculous mycobacteria with descriptions of Mycobacterium bolletii sp. nov., Mycobacterium phocaicum sp. nov. and Mycobacterium aubagnense sp. nov. Int J Syst Evol Microbiol 56:133CrossRef

Toidi A, Martine RG, Gilbert G, Marie-José G, Bernard LS, Didier R, Michel D (2004) Amoebal coculture of “Mycobacterium massiliense” sp. nov. from the sputum of a patient with hemoptoic pneumonia. J Clin Microbiol 42:5493CrossRef

Hee-Youn K, Byoung Jun K, Yoonwon K, Yeo-Jun Y, Jeong Hwan S, Bum-Joon K, Yoon-Hoh K (2010) Mycobacterium massiliense is differentiated from Mycobacterium abscessus and Mycobacterium bolletii by erythromycin ribosome methyltransferase gene (erm) and clarithromycin susceptibility patterns. Microbiol Immunol 54:347–353CrossRef

10.

Toshiyuki H, Yasushi A, Atsuyuki K, Hideaki N, Kazunari T, Takashi F, Syuichi Y, Eriko S, Toshihiko K, Akira K (2012) Clinical and microbiological differences between Mycobacterium abscessus and Mycobacterium massiliense lung diseases. J Clin Microbiol 50:3556–3561CrossRef

11.

Macheras E, Konjek J, Roux AL, Thiberge JM, Bastian S, Leão SC, Palaci M, Sivadon-Tardy V, Gutierrez C, Richter E (2014) Multilocus sequence typing scheme for the Mycobacterium abscessus complex. Res Microbiol 165:82–90CrossRef

12.

Theofano P, Pincus DH, Dorothy G, Melissa J, Josephine B, Julian P, R Andres F, Peter G. (2015) Mycobacterium abscessus complex identification with matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol 53:2355–2358

13.

Mellmann A, Cloud J, Maier T, Keckevoet U, Ramminger I, Iwen P, Dunn J, Hall G, Wilson D, Lasala P (2008) Evaluation of matrix-assisted laser desorption ionization-time-of-flight mass spectrometry in comparison to 16S rRNA gene sequencing for species identification of nonfermenting bacteria. J Clin Microbiol 46:1946–1954CrossRef

14.

Fangous MS, Mougari F, Gouriou S, Calvez E, Raskine L, Cambau E, Payan C, Héry-Arnaud G (2014) Classification algorithm for subspecies identification within the Mycobacterium abscessus species, based on matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol 52:3362–3369CrossRef

15.

Tseng SP, Teng SH, Lee PS, Wang CF, Yu JS, Lu PL (2013) Rapid identification of M. abscessus and M. massiliense by MALDI-TOF mass spectrometry with a comparison to sequencing methods and antimicrobial susceptibility patterns. Future Microbiol 8:1381–1389CrossRef

16.

Kehrmann J, Wessel S, Murali R, Hampel A, Bange FC, Buer J, Mosel F (2016) Principal component analysis of MALDI TOF MS mass spectra separates M. abscessus (sensu stricto) from M. massiliense isolates. BMC Microbiol 16:24CrossRef

17.

Kehrmann J, Kurt N, Rueger K, Bange FC, Buer J (2016) GenoType NTM-DR for identifying Mycobacterium abscessus subspecies and determining molecular resistance. J Clin Microbiol 54:JCM.00147–JCM.00116CrossRef

18.

Mougari F, Loiseau J, Veziris N, Bernard C, Bercot B, Sougakoff W, Jarlier V, Raskine L, Cambau E (2017) Evaluation of the new GenoType NTM-DR kit for the molecular detection of antimicrobial resistance in non-tuberculous mycobacteria. J Antimicrob Chemother 72

19.

Li SY, Cheng QX, Wang JM, Li XY, Zhang ZL, Gao S, Cao RB, Zhao GP, Wang J (2018) CRISPR-Cas12a-assisted nucleic acid detection. Cell Discovery 4:20CrossRef

20.

Li SY, Cheng QX, Liu JK, Nie XQ, Zhao GP, Wang J (2018) CRISPR-Cas12a has both cis- and trans-cleavage activities on single-stranded DNA. Cell Res

21.

Chen JS, Ma E, Harrington LB, Costa MD, Doudna JA. 2018. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. Science 360:eaar6245

22.

Toidi A, Philippe C, Michel D (2003) rpoB-based identification of nonpigmented and late-pigmenting rapidly growing mycobacteria. J Clin Microbiol 41:5699–5708CrossRef

23.

Mikaeili F, Kia EB, Sharbatkhori M, Sharifdini M, Jalalizand N, Heidari Z, Zarei Z, Stensvold CR, Mirhendi H (2013) Comparison of six simple methods for extracting ribosomal and mitochondrial DNA from Toxocara and Toxascaris nematodes. Exp Parasitol 134:155–159CrossRef

24.

Blauwendraat C, Dixon GLJ, Hartley JC, Foweraker J, Harris KA (2012) The use of a two-gene sequencing approach to accurately distinguish between the species within the Mycobacterium abscessus complex and Mycobacterium chelonae. Eur J Clin Microbiol Infect Dis 31:1847–1853CrossRef

25.

Leung JM, Olivier KN (2013) Nontuberculous mycobacteria: the changing epidemiology and treatment challenges in cystic fibrosis. Curr Opin Pulm Med 19:662–669CrossRef

26.

De Zwaan R, van Ingen J, van Soolingen D (2014) Utility of rpoB gene sequencing for identification of nontuberculous mycobacteria in the Netherlands. J Clin Microbiol 52:2544–2551CrossRef

27.

Nie W, Duan H, Huang H, Lu Y, Bi D, Chu N (2014) Species identification of Mycobacterium abscessus subsp. abscessus and Mycobacterium abscessus subsp. bolletii using rpoB and hsp65, and susceptibility testing to eight antibiotics. Int J Infect Dis 25:170–174CrossRef

28.

Hee-Youn K, Yoonwon K, Yeo-Jun Y, Geun PC, Nam Yong L, Tae Sun S, Bum-Joon K, Yoon-Hoh K (2008) Proportions of Mycobacterium massiliense and Mycobacterium bolletii strains among Korean Mycobacterium chelonae-Mycobacterium abscessus group isolates. J Clin Microbiol 46:3384CrossRef

Titel: Identification of Mycobacterium abscessus species and subspecies using the Cas12a/sgRNA-based nucleic acid detection platform
verfasst von: Guohui Xiao
Su Zhang
Zhihang Liang
Guanqiang Li
Mutong Fang
Yaya Liu
Juanjuan Zhang
Min Ou
Xing He
Tianyu Zhang
Changchun Zeng
Lei Liu
Guoliang Zhang
Publikationsdatum: 28.11.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 3/2020
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-019-03757-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Circulatory microRNAs: promising non-invasive prognostic and diagnostic biomarkers for parasitic infections

Non-commercial phenotypic assays for the detection of Mycobacterium tuberculosis drug resistance: a systematic review

Abundance of the nasopharyngeal microbiome effects pertussis diagnosis and explains the sensitivity difference between bacterial culture and real-time PCR

Risk factor analysis for linezolid-associated thrombocytopenia in critically ill patients

Recurrent community-acquired Clostridium(Clostridioides)difficile infection in Serbianchildren